June 26, 2023Open Access

Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study

Key Points

Key points are not available for this paper at this time.

Abstract

Dostarlimab demonstrated durable antitumor activity and safety in patients with dMMR/MSI-H EC. Biomarkers associated with EC may identify patients likely to respond to dostarlimab. See related commentary by Jangra and Dhani, p. 4521.

KI fragen

Bookmark

View Full Paper

Cite This Study

Oaknin et al. (Mon,) studied this question.

synapsesocial.com/papers/69dcc94cf3d3790cb7133d50 https://doi.org/https://doi.org/10.1158/1078-0432.ccr-22-3915

KI fragen

Bookmark

View Full Paper